logo
‘No-brainer' to fund comedy on prescription to aid mental health, MPs hear

‘No-brainer' to fund comedy on prescription to aid mental health, MPs hear

Independent13-03-2025

Funding 'comedy-on-prescription' is a 'no-brainer', MPs have heard, as initial feedback suggests trials of the scheme had a positive impact on people's mental health.
Craic Health secured funding for its social prescribing scheme which uses comedy-based interventions, such as stand-up shows and workshops, to help people who are lonely, isolated and vulnerable get involved in community events.
Labour MP Dr Simon Opher, who helped pioneer social prescriptions in Gloucestershire, has championed the scheme and hopes to ensure comedy can become more 'mainstream in terms of NHS treatment' as an alternative to antidepressants in cases of mild symptoms.
Lu Jackson, the founder of Craic, said responses from surveys completed by those involved in the first five events held between December and March in London had been positive, with nearly all wanting to attend more.
The tech company is looking at whether its 'comedy-on-prescription' approach can help reduce England's mental ill health costs in line with other social prescribing schemes.
NHS figures show 8.7 million people in England took antidepressants in 2023/24, an increase of 2.1% compared with 2022/23.
National Institute for Health and Care Excellence (Nice) guidelines say antidepressants should not be routinely offered as the first treatment for less severe depression unless it is the person's preference.
The One Westminster charity provided a £5,000 grant for Craic's project and Westminster libraries offered their facilities for the initial events.
One Westminster's acting chief executive Shelley Reynolds, speaking at an event in Parliament to discuss the trials and the comedy industry, said: 'It was something that was different, we knew that it would work, we didn't need to see evaluations and outcome reports and numbers and things on a chart to say that works.
'We know if you laugh you feel better so it was a bit of a no-brainer to fund Craic with our little pot of money from the Westminster communities grant.'
Vic Thake, from Westminster libraries, said a 'light went on' when she heard about the comedy-on-prescription project and how it could help underrepresented communities, including older people and those who are homeless.
She said: 'I just thought it was the most amazing idea and something that we could really do that's quite ground-breaking, not only for libraries but for the comedy industry and for the health and wellbeing of our communities.'
Ms Thake added about the trials: 'The plan was formed, it went well and we want to do more of it.'
Ms Jackson said: 'Before the event people were saying they were feeling 3.8 out of six and they were leaving at 5.4 out of six, so that's about a 44% increase in how they felt.'
She added: 'In terms of our future event interest, 98% people are interested and the likelihood of coming to more events was 92%.'
A total of 56 participants completed forms but children who took part in family events were not asked to do so.
Stroud MP Dr Opher said: 'Antidepressants are fantastic medicines and I've seen really great results and some people really, really do well, but one in five of the adult population are on these tablets.
'We need to offer something different to people with mild symptoms. The trouble is you go to the doctor, the doctor has 10 minutes with you, you're referred to a psychologist, you have a six-month wait, there's nothing really they can do so they often prescribe for a lack of other alternatives.'
Dr Opher said social prescribing allows a different approach, adding: 'I'm not saying comedy is going to solve all our emotional problems in this country, and that is certainly far too trite and I really acknowledge that some people really require antidepressants, I must be quite serious on that point.
'However, my feeling is we need to try different things first.'
Dr Opher went on: 'What I'd really, really like to do is to start getting comedy a bit more sort of mainstream in terms of NHS treatment.'
Comedian Jojo Sutherland, founder of Stand Up and Be Counted, said: 'What's happening here is a connection between people that have to come together in order to address this absolute tsunami of mental health that is coming down the river to hit us.
'The idea that there's 8.7 million people on antidepressants is appalling.'
She said many of the best comedians talk about their experiences of addiction, trauma, abuse, depression and suicidal tendencies, adding: 'That's why comedy is so ideally placed to actually work with people in the community.'
Ryan Renehan, a social prescriber from One Westminster involved in the project, said social prescribing can help people rediscover things they enjoy and foster connections in the community.
He said: 'A good analogy I like to think about is if you picture yourself in a room in the dark and there isn't any light in there, you might think social prescribing's role is to turn on the lights for them, but it's not, it's to help them find that switch for themselves.
'And in the future when they're in another room where there isn't any light, they can reach out and look for that switch themselves.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Cruel' postcode lottery to access life-changing drug
‘Cruel' postcode lottery to access life-changing drug

The Independent

timean hour ago

  • The Independent

‘Cruel' postcode lottery to access life-changing drug

Parents of children with Duchenne muscular dystrophy are struggling to access a free drug, givinostat, on the NHS due to limited availability and a " postcode lottery" system described by a charity as 'cruel'. Givinostat, which slows the progression of Duchenne and prolongs walking ability in children, is offered at no cost by a drug firm while it awaits NHS approval. Some NHS trusts are reportedly delaying or refusing access, citing monitoring costs (approximately £1,900 per patient annually) as a barrier, while others are drawing up priority lists. Duchenne UK, a charity, is assisting families in their fight for givinostat, while the government maintains the decision rests with individual NHS trusts. NHS England says that the first NICE committee meeting to consider the treatment is scheduled for July, and it is ready to explore fast-tracking access if the manufacturer offers a cost-effective price.

Horsham parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Horsham parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

ITV News

time2 hours ago

  • ITV News

Horsham parents whose sons are losing ability to walk face ‘nightmare' battle with NHS

Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'

NHS England to roll out pioneering cancer treatment in world first
NHS England to roll out pioneering cancer treatment in world first

The Independent

time2 hours ago

  • The Independent

NHS England to roll out pioneering cancer treatment in world first

NHS England will be the first health system worldwide to roll out the pioneering "Trojan horse" treatment, belantamab mafodotin (Blenrep), for blood cancer patients. The targeted therapy has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, benefitting approximately 1,500 patients annually. Blenrep, manufactured by GlaxoSmithKline, has been approved by the National Institute for Health and Care Excellence (Nice) for use within the NHS. It will be available to patients whose cancer has advanced or has not responded to initial treatments. Trials suggest that the treatment, in combination with other drugs, delayed disease progression by an average of three years, compared to just over a year for patients taking commonly used drugs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store